Role of Proviral HIV-1 DNA Genotyping for People Living with HIV (PLWH) Who Had Low-Level Viremia While Receiving Antiretroviral Therapy

References

• Lohse N, Obel N. Update of Survival for Persons With HIV Infection in Denmark. Ann Intern Med. 2016;165(10):749–750. doi:10.7326/L16-0091
   PubMed Web of Science ®Google Scholar
• Li Q, Chen M, Zhao H, et al. Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: a Retrospective Cohort Study in China. Infect Drug Resist. 2021;14:4529–4537. doi:10.2147/IDR.S332924.eCollection2021
   PubMed Web of Science ®Google Scholar
• Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials. 2009;10(2):116–124. doi:10.1310/hct1002-116
   PubMed Web of Science ®Google Scholar
• Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010;201(9):1303–1307. doi:10.1086/651618
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One. 2012;7(5):e36673. doi:10.1371/journal.pone.0036673
   PubMed Web of Science ®Google Scholar
• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2021. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed April 1, 2023.
   Google Scholar
• WHO. Update of recommendations on first-and second-line antiretroviral regimens: HIV treatment; 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/325892/WHOCDS-HIV-19.15-eng.pdf. Accessed April 1, 2023.
   Google Scholar
• Delaugerre C, Braun J, Charreau I, et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med. 2012;13(9):517–525. doi:10.1111/j.1468-1293.2012.01002.x
   PubMed Web of Science ®Google Scholar
• Wirden M, Soulie C, Valantin MA, et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother. 2011;66(4):709–712. doi:10.1093/jac/dkq544
   PubMed Web of Science ®Google Scholar
• Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One. 2015;10(1):e0117430. doi:10.1371/journal.pone.0117430
   PubMed Web of Science ®Google Scholar
• Lambert-Niclot S, Allavena C, Grude M, et al. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. J Antimicrob Chemother. 2016;71(8):2248–2251. doi:10.1093/jac/dkw146
   PubMed Web of Science ®Google Scholar
• Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145–2152. doi:10.1093/cid/ciz129
   PubMed Web of Science ®Google Scholar
• Hosmane NN, Kwon KJ, Bruner KM, et al. Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J Exp Med. 2017;214(4):959–972. doi:10.1084/jem.20170193
   PubMed Web of Science ®Google Scholar
• Simonetti FR, Sobolewski MD, Fyne E, et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S A. 2016;113(7):1883–1888. doi:10.1073/pnas.1522675113
   PubMed Web of Science ®Google Scholar
• Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530(7588):51–56. doi:10.1038/nature16933
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111(6):2307–2312. doi:10.1073/pnas.1318249111
   PubMed Web of Science ®Google Scholar
• Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307. doi:10.1016/j.meegid.2016.08.031
   PubMed Web of Science ®Google Scholar
• Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. Aids. 2019;33(13):2005–2012. doi:10.1097/QAD.0000000000002306
   PubMed Web of Science ®Google Scholar
• Elvstam O, Marrone G, Medstrand P, et al. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: results From a Swedish Nationwide Observational Study. Clin Infect Dis. 2021;72(12):2079–2086. doi:10.1093/cid/ciaa413
   PubMed Web of Science ®Google Scholar
• Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651–1669. doi:10.1001/jama.2020.17025
   PubMed Web of Science ®Google Scholar
• Brodin J, Zanini F, Thebo L, et al. Establishment and stability of the latent HIV-1 DNA reservoir. Elife. 2016;5. doi:10.7554/eLife.18889
   PubMed Web of Science ®Google Scholar
• Arias A, López P, Sánchez R, et al. Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments. Int J Environ Res Public Health. 2018;15(8). doi:10.3390/ijerph15081697
   Web of Science ®Google Scholar
• Huruy K, Mulu A, Liebert UG, et al. HIV-1C proviral DNA for detection of drug resistance mutations. PLoS One. 2018;13(10):e0205119. doi:10.1371/journal.pone.0205119
   PubMed Web of Science ®Google Scholar
• Zaccarelli M, Santoro MM, Armenia D, et al. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. J Clin Virol. 2016;82:94–100. doi:10.1016/j.jcv.2016.07.007
   PubMed Web of Science ®Google Scholar
• Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis. 2009;48(2):239–247. doi:10.1086/595703
   PubMed Web of Science ®Google Scholar
• Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43(1):406–413. doi:10.1128/JCM.43.1.406-413.2005
   PubMed Web of Science ®Google Scholar
• Wang C, Mitsuya Y, Gharizadeh B, et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007;17(8):1195–1201. doi:10.1101/gr.6468307
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Kwon P, Nettles RE, et al. G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005;79(3):1975–1980. doi:10.1128/JVI.79.3.1975-1980.2005
   PubMed Web of Science ®Google Scholar
• Boukli N, Boyd A, Collot M, et al. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads. J Antimicrob Chemother. 2018;73(11):3129–3136. doi:10.1093/jac/dky316
   PubMed Web of Science ®Google Scholar
• Charpentier C, Montes B, Perrier M, et al. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study. J Antimicrob Chemother. 2017;72(10):2831–2836. doi:10.1093/jac/dkx233
   PubMed Web of Science ®Google Scholar
• Fourati S, Malet I, Lambert S, et al. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. Aids. 2012;26(13):1619–1624. doi:10.1097/QAD.0b013e3283560703
   PubMed Web of Science ®Google Scholar
• Allavena C, Rodallec A, Leplat A, et al. Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy. J Virol Methods. 2018;251:106–110. doi:10.1016/j.jviromet.2017.10.016
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Paraskevis D, et al. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses. 2007;23(9):1078–1082. doi:10.1089/aid.2006.0287
   PubMed Web of Science ®Google Scholar
• Turriziani O, Bucci M, Stano A, et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr. 2007;44(5):518–524. doi:10.1097/QAI.0b013e3180315515
   PubMed Web of Science ®Google Scholar
• Kabamba-Mukadi B, Duquenne A, Henrivaux P, et al. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med. 2010;11(8):483–492. doi:10.1111/j.1468-1293.2009.00814.x
   PubMed Web of Science ®Google Scholar